Alembic Of India Plans Focus Switch From Local Market To Europe, U.S.
This article was originally published in PharmAsia News
India's Alembic Pharma plans to shift from producing active pharmaceutical ingredients for the local market to focus on Europe and the United States, which it believes offer greater profitability.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.